Related Experiment Videos

Folinic acid protects against suppression of growth by methotrexate in mice

M P Iqbal1, F Sultana, N Mehboobali

  • 1Department of Biological & Biomedical Sciences, The Aga Khan University, PO Box 3500, Stadium Road, Karachi, Pakistan. perwaiz.iqbal@aku.edu

Insights

Folinic acid supplementation protects young mice from growth suppression caused by methotrexate (MTX). This study shows folinic acid can mitigate MTX

Area of Science:

  • Pharmacology
  • Developmental Biology
  • Toxicology

Background:

  • Methotrexate (MTX) is a chemotherapy agent used to treat various cancers and autoimmune diseases.
  • MTX can cause significant side effects, including growth suppression, particularly in young patients.
  • Folinic acid is a derivative of folic acid that can counteract some of MTX's toxic effects.

Purpose of the Study:

  • To investigate the protective effect of folinic acid supplementation against MTX-induced growth suppression in young mice.
  • To explore the underlying mechanisms of MTX toxicity and folinic acid's protective role.

Main Methods:

  • Four groups of young male mice were treated with MTX alone, folinic acid alone, MTX plus folinic acid, or saline (control).
  • Body weight, food and water consumption were monitored over 3 weeks.
  • Organ weights (liver, spleen, kidneys) and histological changes in the small intestine, liver, and kidneys were analyzed.
  • MTX levels and dihydrofolate reductase activity in the liver were measured.

Main Results:

  • Mice treated with MTX alone exhibited minimal weight gain and reduced organ weights compared to control and folinic acid-treated groups.
  • MTX treatment led to intestinal villous atrophy and altered MTX/dihydrofolate reductase levels in the liver.
  • Co-administration of folinic acid with MTX significantly ameliorated these negative effects.

Conclusions:

  • Folinic acid effectively protects against MTX-induced growth suppression in young mice.
  • The protective mechanism involves counteracting MTX's inhibition of de novo DNA synthesis and preserving intestinal morphology.
  • Patients receiving long-term MTX therapy, such as those with juvenile rheumatoid arthritis or acute lymphoblastic leukemia, may benefit from folinic acid supplementation to prevent growth suppression.

Related Concept Videos